An anti-OX40 antibody to treat moderate-to-severe atopic der

Patients treated with rocatinlimab had progressive improvements in atopic dermatitis,
which was maintained in most patients after treatment discontinuation. Treatment was
well tolerated.

Related Keywords

Germany , Japan , United States , Canada , American , , American Academy Of Dermatology Consensus Criteria , American Academy , Dermatology Consensus Criteria , Eczema Area , Severity Index , Global Assessment , Atopic Dermatitis ,